Cytori (NASDAQ:CYTX) Patent in Australia
CYTX has received a patent covering methods of treating cardiovascular disease using adipose-derived regenerative cells (ADRCs) from the Australian Therapeutic Goods Administration (NASDAQ:TGA) with the Celution® System being approved for commercial use through inclusion on the TGA for autologous re-implantation and re-infusion of a patient's own ADRCs
The patent covers the therapeutic use of ADRCs for improving cardiac function and mechanics by preventing the deleterious histopathological and structural changes that occur in the heart following a heart attack (cardiac remodeling).
The patent is not limited to any particular way of obtaining ADRCs, covering both manual and automated methods of obtaining the cells. This includes the use of a sterile, closed system such as the proprietary Celution® System. The claims also cover multiple cell populations and cell delivery methods, including intravenous delivery.
The Bottom Line: This approval enables physicians to treat critical unmet medical needs with point-of-care cell therapies and to conduct important clinical research in promising therapeutic areas. The patent complements Cytori's existing patents in Australia covering the Celution® System.
CYTX closed at $2.16, with a winnowing version of its past share price <consider it was trading at $2.81 on 8/1/13 and $2.80 on 1/2/13 versus $2.14 on 5/21/12. Where the next version of … testosterone as the cash position is dwindles with a 52 week change of -49.41% and the 52 week low was $2.09? Volume has hugged the low end of the 3 month metric noticing the only big day of 1.1 M on 9/20/13. A … HOLD until some granular news is evident.
Where's the meat?
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.